Vaxart Reports Q2 2025 Earnings and Vaccine Progress

Vaxart ( (VXRT) ) has released its Q2 earnings. Here is a breakdown of the information Vaxart presented to its investors.

Vaxart, Inc. is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform, targeting diseases such as coronavirus, norovirus, and influenza. In its latest earnings report for the second quarter of 2025, Vaxart highlighted significant progress in its vaccine development programs, including positive topline data from its Phase 1 clinical trial for a second-generation oral norovirus vaccine and substantial enrollment in its COVID-19 Phase 2b trial before a stop work order was issued. The company reported a revenue increase to $39.7 million, primarily from government contracts, and a net loss of $15.0 million, showing an improvement from the previous year. Vaxart’s research and development expenses rose significantly due to ongoing clinical trials, while general and administrative expenses decreased. Looking ahead, Vaxart plans to continue advancing its vaccine candidates through clinical trials, with a focus on securing partnerships and funding to extend its cash runway and achieve regulatory milestones.